Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines

Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines

IntroductionThe CD6‐CD318 axis has emerged as a potential target for immuno‐oncology. Recent work has shown that blocking the CD6‐CD318 interaction with a murine anti‐human CD6 antibody increases lymphocyte cytotoxicity. However, several studies have demonstrated the drawbacks associated with the cl...

Full description

Saved in:
Bibliographic Details
Main Authors: Cynthia González Muñoz, Rydell Álvarez Arzola, Adanays Calvo Pérez, Milagro de la Caridad Frometa Campanón, Patricia Hernández Casaña, Aymé Fernández-Calienes Valdés, Patricia Lorenzo-Luaces, Zaima Mazorra Herrera, Tania Crombet Ramos, Mayrel Labrada Mon
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
CD6
CD318
ALCAM(CD166)
CD5
NK cells
CD8 lymphocytes
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1585597/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1585597/full

Similar Items